A major limit for in vivo studies is the different cellular distribution of the IgE high-affinity receptor. In mice, the IgE high-affinity receptor is not expressed on monocytes/DCs, Langerhans cells, or eosinophils whereas it is in humans.

The model enables the production of a fully human IgE-FcεRI complex combined with a human-like expression of a FcεRI receptor.

hIgE/hFcεR1 model features

  • Human-like cellular distribution (i.e., mast cells, basophils, monocytes/DCs, Langerhans cells, and eosinophils) of the FcεR1 receptor due to the presence of a minimal human promoter that drives its expression
  • Physiological regulation and expression of the chimeric IgE/FcεR1 complex [humanized IgE/FcεR1 interactive domains (i.e., IgE Fc region and FcεR1 α-chain), and murine IgE Fab region and FcεR1 β- and γ-chains]

Validation

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results

Discover related products to

hIgE/hFcεR1

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mouse
cGAS
cGAS-STING pathway

hcGAS

The hcGAS mouse enables the in vivo assessment of agents and therapies targeting the cGAS–STING cytosolic DNA sensing pathway in fully immunocompetent mice.

Mouse
TFRC
Cell shuttling

hTFRC

The hTFRC mouse model enables in vivo efficacy assessment and profiling of compounds targeting the human cell shuttle TFRC in fully immunocompetent mice.

Mouse
Reporter
IL-4

IL-4-IRES-eGFP

The reliable monitoring and sorting of IL-4-secreting cells allows you to efficiently delineate the immune response polarization toward the Th2 pathway.

Mouse
Reporter
Foxp3

Foxp3-IRES-mRFP

This reliable Foxp3 reporter mouse allows you to efficiently monitor/sort Foxp3-expressing cells from different lymphocyte lineages & lymphoid organs

Humanized targets
Mouse
HSA
PK/PD
Immunodeficient

HSA/hFcRn-Rag1-KO

This upgraded, immunocompromised Rag1-/- version of our HSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

BRGSF
Immunodeficient
Mouse

BRGSF

Compared to NOD-SCID and NSG, the BRGSF mouse represents the most adapted animal model to study and predict human immune responses in vivo.

Mouse
HIS
BRGSF
Immunodeficient

BRGSF-A2-HIS

BRGSF-A2-HIS mice possess the most functional reconstituted human immune system. HLA molecules on thymic epithelial cells hinder T-cell cross-reactivity.

Mouse
Humanized targets
Inflammation
TNF

hTNF-α

The hTNF-α model provides new opportunities for assessment of anti-TNF therapies.

Mouse
CD4
Inflammation

hCD4

The human CD4 mouse model allows in vivo efficacy and safety assessment of anti-human CD4 compounds.

Mouse
ICP
Humanized targets
PD-1
GITR

hPD-1/hGITR/hGITRL

The hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Mouse
ICP
Humanized targets
VISTA
ICP (single-target)

hVISTA

The hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Mouse
STING
cGAS-STING pathway

hSTING

The hSTING mouse enables the in vivo assessment of agents and therapies targeting  the human immune checkpoint STING in fully immunocompetent mice.

Mouse
ICP
Humanized targets
OX40
ICP (single-target)

hOX40

The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Mouse
ICP
Humanized targets
GITR
ICP (single-target)

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Mouse
ICP
Humanized targets
CTLA-4
ICP (single-target)

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Mouse
ICP
Humanized targets
CD39
ICP (single-target)

hCD39

The hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Mouse
ICP
Humanized targets
CD28
ICP (single-target)

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Mouse
ICP
PD-1
PD-L1
ICP (multi-target)

hPD-1/hPD-L1

The hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Mouse
ICP
Humanized targets
PD-1
Lag3

hPD-1/hLAG3

The hPD-1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Mouse
ICP
PD-1
VISTA
Humanized targets

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Mouse
ICP
PD-1
TIM3
Humanized targets

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Mouse
ICP
Reporter
Humanized targets
GITR

hGITR/Foxp3

The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.

Mouse
ICP
Humanized targets
GITR
GITRL

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Mouse
ICP
Humanized targets
CTLA-4
PD-1

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Mouse
ICP
Humanized targets
CTLA-4
Lag3

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Cells
PD-L1
ICP
Humanized targets
MC38

MC38-hPD-L1-LZ

The MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

CD39
Cells
MC38
Humanized targets
Reporter

MC38-hCD39-LZ

The  MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form  infiltrated tumors in immunocompetent mice.

CD20
Cells
ICP
Humanized targets
Reporter

EL4-hCD20-LZ

The  EL4-hCD20-LZ clonal cell line expresses high levels of human CD20.

CD19
EL4
Humanized targets
Cells
ICP

EL4-hCD19-LZ

EL4-hCD19-LZ cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.

CT26
Cells
ICP
Humanized targets
EpCAM

CT26-hEpCAM-LZ

CT26-hEpCAM-LZ  clonal cell line expresses high levels of human EpCAM, and forms solid tumors in vivo.

CT26
Cells
ICP
Humanized targets
CD39

CT26-hCD39-LZ

The CT26-hCD39-LZ clonal cell line expresses high levels of human/mouse chimeric CD39, and forms solid tumors in vivo.

PD-L1
Cells
ICP
Humanized targets

CT26-hPD-L1

The humanized PD-L1 syngeneic clonal colon carcinoma CT26 cell line expresses high levels of human PD-L1 and forms solid tumors in vivo.

T-cell engager
CD3
Humanized targets
Mouse

hCD3ε

hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

Humanized targets
Mouse
PD-1
ICP
ICP (single-target)

hPD-1

The hPD-1 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 in fully immunocompetent mice.

CD3
Humanized targets
Mouse
CD28
T-cell engager

hCD3ε/hCD28

hCD3ε  immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

Humanized targets
Mouse
HSA
PK/PD

HSA/hFcRn

Use this double humanized HSA/hFcRn mouse model for accurate and predictive PK/PD studies of albumin- and FcRn-binding compounds.

Mouse
BRGSF
HIS
Immunodeficient

BRGSF-HIS

BRGSF-HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

Humanized IgE/FcεR1 mouse model

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.